Personalised Integrated Biomaterial Risk Assessment (PANBIORA)
Standardized biomaterial assessment opens the space for personalized preimplantation diagnostics. PANBioRA will for the first time be able to predict a patient's response to a specific biomaterial before it is implanted. These measures will allow selection of the best material, minimize side effects and improve health outcomes.
The PANBioRA testing system allows for improved, faster and more cost-effective evaluation of biomaterials. In the first project period, the focus was on the further development of the PANBioRA system and the linking of the different components. In addition, the first version of a risk assessment system based on multi-criteria decision analysis was developed. Clinical samples were collected and tested, and initial planning steps were taken for the commercial launch of the prototype.
With the completion of the second reporting period, the project received excellent feedback from the European Commission, which stated that "some of the specific research tasks have a very strong innovation potential that will undoubtedly be welcomed by stakeholders involved in the risk management of new nano-biomaterials." The final phase of the project will also focus on the exploitation of the knowledge gathered and possible patent applications.
As project coordinator, Steinbeis Europa Zentrum is responsible for administrative project coordination, communication, dissemination of project results and IPR management.
- Project name acronym: PANBioRA
- Funding: European Commission, Horizon 2020
- Funding budget for all partners: 8 Mio. EUR
- Participating countries: Albania, Belgium, Czech Republic, Estonia, Finland, France, Germany, Ireland, Serbia, Spain, UK
- Project duration: 01/2018 – 12/2021
Keywords: Personalised Medicine, Biomaterials, Research Cooperation
Personalised and generalised integrated biomaterial risk assessment